Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,369 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06343038RecruitingPhase 1
A new targeted radiation drug for advanced prostate cancer
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
BaselAges 18 years+ - NCT07476001RecruitingPhase 2
High-dose testosterone and PSMA-targeted radiation for prostate cancer
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
Tampa, FloridaAges 18 years+ - NCT06962137RecruitingPhase 2
Zolbetuximab plus two chemos for CLDN18.2-positive stomach cancer
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
AntwerpAges 18 years+ - NCT07235202RecruitingPhase 1/Phase 2
MR001 plus chemo for advanced pancreatic cancer after first treatment
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06479759RecruitingPhase 2
LM-108 with sintilimab for advanced lung cancer
This trial tests a new antibody combination for non-small cell lung cancer that has spread or come back. It may help people whose cancer stopped responding to immunotherapy or who haven't had treatment yet.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07646171Recruiting
Everolimus After Alpelisib for Advanced Breast Cancer
This trial tests a drug called everolimus in women with hormone receptor-positive metastatic breast cancer who have already tried alpelisib (a PI3K inhibitor) combined with hormone therapy. The goal is to see if this next treatment can help control cancer growth.
Tel AvivAges 21 years+ - NCT06242509Recruiting
Akkermansia bacteria in prostate cancer
This trial looks at whether a specific gut bacterium, Akkermansia muciniphila, is linked to how well hormone therapy works in men with advanced prostate cancer that no longer responds to standard hormone treatment. You may join if you are about to start a new type of hormone therapy.
ParisAges 18–100 - NCT07007910RecruitingPhase 1
Study of HSK46575 for advanced prostate cancer
This trial tests a new drug, HSK46575, for men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy and chemotherapy. The goal is to see if it can help slow the cancer's growth.
Chengdu, SichuanAges 18 years+ - NCT07298239RecruitingEarly Phase 1
CAR-NK cell therapy for advanced prostate cancer
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
Beijing, 不限Ages 18 years+ - NCT06126666RecruitingPhase 1
ABL103 for advanced solid tumors
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Seongnam, SeoulAges 18 years+ - NCT07012954RecruitingPhase 1/Phase 2
ctDNA-guided treatment for RAS/BRAF wild-type colorectal cancer
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
Guangzhou, GuangdongAges 18–75 - NCT06100705RecruitingPhase 2
Combination therapy for men with advanced prostate cancer
This trial tests combining an immunotherapy (Sipuleucel-T) with high-dose testosterone to see if it works better for men with castration-resistant prostate cancer that has spread.
New Haven, ConnecticutAges 18 years+ - NCT07193862RecruitingEarly Phase 1
Testing a tiny device to find best treatments for liver tumors
This study tests a tiny device that is placed in your liver tumor during surgery. It checks how well different chemotherapy drugs work on your specific cancer, which may help your doctor choose the best treatment for you.
Lake Success, New YorkAges 18 years+ - NCT07040228RecruitingPhase 1/Phase 2
Study of regorafenib, toripalimab, and chemo for advanced pancreatic cancer
This trial tests a combination of three drugs (regorafenib, toripalimab, and albumin-bound paclitaxel) as a third-line treatment for advanced pancreatic cancer that has progressed after two prior therapies. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Shenzhen, GuangdongAges 18–80 - NCT04174352RecruitingEarly Phase 1
FES scan to guide tamoxifen for metastatic breast cancer
This early-phase study uses a special PET scan (FES PET/CT) to better match tamoxifen treatment to people with estrogen-receptor–positive breast cancer that has spread. It aims to see whether the scan results can help optimize tamoxifen use and potentially improve outcomes.
Madison, WisconsinAges 19 years+ - NCT06640413RecruitingPhase 1
Study of radioactive treatment for FAP-positive advanced tumors
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
Bergamo, BergamoAges 18 years+ - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT07223411Recruiting
Opdualag vs. cemiplimab/fianlimab for melanoma
This trial compares two treatments for advanced melanoma that cannot be removed with surgery or has spread. It studies how these treatments affect the immune response in tumors and blood, and requires extra biopsies and blood draws.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06642844RecruitingPhase 3
Bevacizumab dose adjustment for colorectal cancer
This trial tests whether adjusting the dose of bevacizumab based on your blood levels can improve first-line treatment for metastatic colorectal cancer that can't be removed with surgery.
BesançonAges 18–99 - NCT07673029RecruitingPhase 3
Comparing two treatments for HER2-positive breast cancer
This trial compares a new drug, GQ1005, with an existing treatment called T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see which one works better for those who have already received certain other treatments.
Bengbu, AnhuiAges 18–75 - NCT06106802RecruitingPhase 2
Testing lazertinib and tepotinib for EGFR lung cancer that progressed on lazertinib
This trial tests a combination of two targeted drugs, lazertinib and tepotinib, for people with advanced EGFR-mutant non-small cell lung cancer whose tumors show MET overactivity (high MET levels or MET gene copies) and have grown despite prior treatment with lazertinib. It aims to see if adding tepotinib can overcome that resistance.
Seoul, Gangnam-guAges 19 years+ - NCT07048457RecruitingPhase 2
Surgery for metastatic bladder cancer after initial treatment
This trial tests whether removing the primary bladder tumor and any remaining metastatic spots after initial medication (enfortumab-vedotin) improves outcomes for people with a limited number of metastases (5 or fewer). It is for those whose cancer has responded or stabilized on treatment.
New Haven, ConnecticutAges 18 years+ - NCT07646626RecruitingPhase 2
New antibody drugs for advanced HER2-positive cancers
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
Hangzhou, ZhejiangAges 18–75 - NCT07633353Enrolling by invitation
Real-World Outcomes of a New Treatment for Advanced Kidney Cancer
This study looks at how well two newer cancer drugs (enfortumab vedotin and pembrolizumab) work together for advanced upper tract urothelial carcinoma—a rare kidney cancer. Researchers are collecting information from hospitals in France to understand how patients respond and what side effects occur in everyday care.
NîmesAges 18 years+
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,369 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.